490
Participants
Start Date
September 1, 2022
Primary Completion Date
October 1, 2025
Study Completion Date
December 30, 2025
LBL-007 Injection
Initial dose - MTD; Q3W; intravenous infusion
Tislelizumab Injection
Initial dose; Q3W; intravenous infusion
Cisplatin Injection
Initial dose；Q3W; intravenous infusion
Gemcitabine Hydrochloride for Injection
Initial dose；Q3W; intravenous infusion
Docetaxel injection
Initial dose；Q3W; intravenous infusion
RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
RECRUITING
Anhui Cancer Hospital, Hefei
RECRUITING
Zhejiang Cancer Hospital, Hangzhou
RECRUITING
Jiangxi Cancer Hospital, Nanchang
RECRUITING
Fujian Cancer Hospital, Fuzhou
RECRUITING
Hunan Cancer Hospital, Changsha
RECRUITING
Hubei Cancer Hospital, Wuhan
RECRUITING
Union Hospital Tongji Medical College Huazhong University of Science And Technology, Wuhan
RECRUITING
The Jiangmen Central Hospital, Jiangmen
RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
RECRUITING
Sun Yat-Sen Memorial Hospital，Sun Yat-Sen University, Guangzhou
RECRUITING
Huizhou Municipal Central Hospital, Huizhou
NOT_YET_RECRUITING
Central People's Hospital of Zhanjinag, Zhanjiang
NOT_YET_RECRUITING
Maoming People's Hospital, Maoming
RECRUITING
Guangxi Tumour Hospital, Nanning
RECRUITING
The First Affiliated Hospital of Guangxi Medical University, Nanning
RECRUITING
The First People's Hospital of Yu Lin, Yulin
RECRUITING
The Second Affiliated Hospital of Hainan Medical University, Haikou
RECRUITING
West China Hospital of Sichuan University, Chengdu
Nanjing Leads Biolabs Co.,Ltd
INDUSTRY